Rheumatology

  • FDA approves first specific treatment for giant cell arteritis

    on May 22nd, 2017
    The Food and Drug Administration has approved subcutaneous tocilizumab (Actemra) for the treatment of giant cell arteritis, according to a May 22 announcement from the agency. Giant cell arteritis is a type of vasculitis that inflames blood vessels in the head, causing arteries to narrow or become i[...]
  • Intervention improves use of treat to target in RA

    on May 19th, 2017
    FROM ARTHRITIS & RHEUMATOLOGY A learning collaborative approach can significantly improve adherence to a treat-to-target approach in patients with rheumatoid arthritis, new research suggests. While numerous clinical trials have shown that a strategy of treating to target achieves better outcomes[...]
  • Mepolizumab proves effective for eosinophilic granulomatosis with polyangiitis

    on May 17th, 2017
    FROM NEW ENGLAND JOURNAL OF MEDICINE Adding mepolizumab to standard-of-care glucocorticoids with or without immunosuppressive agents can induce remission in many patients who have eosinophilic granulomatosis with polyangiitis (EGPA), according to a report published online May 18 in the New England J[...]
  • Screen for comorbidities in pyoderma gangrenosum

    on May 17th, 2017
    AT SID 2017 PORTLAND, ORE. (FRONTLINE MEDICAL NEWS) – Comorbidities were common in patients with pyoderma gangrenosum (PG), in a single-center retrospective cohort study of 130 patients. These comorbid diagnoses were not only clinically significant in themselves, but also were associated with chan[...]
  • Long-term TNFi tapering possible for some with ankylosing spondylitis

    on May 15th, 2017
    AT RHEUMATOLOGY 2017 BIRMINGHAM, ENGLAND (FRONTLINE MEDICAL NEWS) – A proportion of patients with ankylosing spondylitis (AS) were able to remain on a reduced-dose regimen of a tumor necrosis factor inhibitor (TNFi) for almost 4 years, according to data from a small study presented at the British [...]
  • CC-220 shows efficacy, safety concerns in phase II SLE trial

    on May 15th, 2017
    AT SID 2017 PORTLAND (FRONTLINE MEDICAL NEWS) – The investigational agent CC-220 showed some efficacy but important safety signals in a 12-week, phase II, dose-escalation study of 42 patients with systemic lupus erythematosus (SLE). In all, 14% of patients stopped treatment because of adverse effe[...]
  • Depressed OA patients get far-reaching benefits from Internet-delivered CBT

    on May 15th, 2017
    FROM ARTHRITIS CARE & RESEARCH Cognitive behavioral therapy administered online can effectively treat symptoms of depression in older people with knee osteoarthritis, according to results from the first randomized trial of its kind. The benefits of the 10-week program extended to improving pain,[...]
  • Ankylosing spondylitis disease severity worsened by smoking

    on May 12th, 2017
    AT RHEUMATOLOGY 2017 BIRMINGHAM, ENGLAND (FRONTLINE MEDICAL NEWS) – Patients with axial spondyloarthritis who currently smoke have been found to have worse disease activity than those who do not in an early analysis of data from the British Society for Rheumatology Biologics Register for Ankylosin[...]
  • SLE linked to subsequent risk of malignant melanoma

    on May 11th, 2017
    AT SID 2017 PORTLAND, ORE. (FRONTLINE MEDICAL NEWS) – A diagnosis of systemic lupus erythematosus (SLE) significantly increases the risk of a subsequent diagnosis of malignant melanoma, according to the results of a large, first-in-kind, single-center longitudinal analysis of electronic medical re[...]
  • Cutaneous manifestations can signify severe systemic disease in ANCA-associated vasculitis

    on May 9th, 2017
    PORTLAND, ORE. (FRONTLINE MEDICAL NEWS) – Clinicians who treat or diagnose ANCA-associated vasculitis should watch for a variety of skin lesions, which can signify severe systemic manifestations of disease, according to the results of a cross-sectional study of 1,184 patients from 130 centers worl[...]
  • Dalbavancin proves highly effective in osteomyelitis

    on May 9th, 2017
    AT ECCMID 2017 VIENNA (FRONTLINE MEDICAL NEWS) – Two infusions of the long-acting lipoglycopeptide antibiotic dalbavancin showed a favorable clinical benefit for treatment of adult osteomyelitis in a phase II study. Dalbavancin (Dalvance) showed positive results while avoiding the complexities of [...]
  • Antacid use in infants linked to increased fracture risk

    on May 9th, 2017
    AT PAS 17 SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – Children were more likely to experience a fracture if they were prescribed antacids before age 1 year, according to a study of military families. The large study revealed that use of proton pump inhibitors (PPIs) before age 1 year was linked to a [...]
  • Think twice before recommending partial meniscectomy

    on May 9th, 2017
    AT OARSI 2017 LAS VEGAS (FRONTLINE MEDICAL NEWS) – Patients with knee osteoarthritis (OA) and a meniscal tear who underwent arthroscopic partial meniscectomy (APM) subsequently experienced accelerated structural progression of their OA, compared with those randomized to physical therapy alone in t[...]
Back to top